Clinical trials: Healthy Humans
Autoimmune Diseases
Phase 0 Microdose Study
This study is a methodology study to evaluate a microdose strategy for Drug-Drug Interaction (DDI) which will be useful in the evaluation of the backup compounds for GSK706769, as well as possibly other assets.
- Trial name
- NCT00975936
- Testing
- [14C]-GSK706769, Ketoconazole
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections
A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese Men
The pre-exposure prophylaxis (PrEP) is an important component in the overall strategy for prevention of HIV infection. Cabotegravir (CAB) is an integrase strand transfer inhibitor currently in development for treatment and…
- Trial name
- NCT03422172
- Testing
- Oral CAB, CAB LA
- Where
- 3 sites in China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Dengue
An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge
The investigational study drug, JNJ-64281802, is being developed for the prevention and treatment of dengue infection. This study is hypothesizing that the highest dose of the investigational study drug is superior to receiving a…
- Trial name
- NCT05048875
- Testing
- Cohort 1 - Group 1 JNJ High Dose, Cohort 1 - Group 2 JNJ Medium Dose, Cohort 1 - Group 2 JNJ Low Dose
- Where
- 2 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Escherichia Infection
Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults
The study is designed to evaluate the safety, immunogenicity, and efficacy of the intramuscular administration of a CS6 based vaccine (CssBA) against ETEC co-administered with double mutant labile toxin (dmLT) in preventing…
- Trial name
- NCT06692907
- Testing
- B7A (ETEC challenge strain), CssBA, dmLT
- Where
- 2 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C
Single-Dose Escalation Study of IDX184 in Healthy Volunteers (MK-2355-002)
The purpose of this study is to obtain single dose safety and pharmacokinetic (PK) data of IDX184 in humans. No formal hypotheses are to be tested in this study.
- Trial name
- NCT00730431
- Testing
- IDX184
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Bioavailability Heathy Volunteers
Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone
To study intrasubject variability and steady-state pharmacokinetics of multiple-doses of Extended Release Torsemide and Spironolactone Fixed Dose Combination (FDC) tablets given together in healthy adult subjects.
- Trial name
- NCT07046975
- Testing
- Torsemide and Spironolactone tablet, Torsemide Tablets and Spironolactone Tablets
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sarfez Pharmaceuticals, Inc.
Changes in Human Gut Microbiome in Healthy Adults
Prospective Randomized Controlled Pilot Study of Gut Microbiome Modulation by Nigella Sativa Seed Oil and Thymoquinone Metabolism in Healthy Volunteers
For many patients, the additive use of dietary supplements without side effects is motivating for therapy and enhances quality of life.
- Trial name
- NCT07450807
- Testing
- Intake of Thymoquinone (TQ) containing Nigella Sativa Seed Oil (NSSO) capsules
- Where
- Germany
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Aysun Tekbaş
Healthy Volunteer
First-in-human Study of HSK56630 in Healthy Subjects
This is a first-in-human, single ascending dose (SAD) study in healthy adult participants. This is a single-center, randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability and PK of HSK56630…
- Trial name
- NCT07580794
- Testing
- HSK56630
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Infection, Human Immunodeficiency Virus
Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine
This study aims to compare the bioequivalence of two experimental fixed dose combination (FDC) tablets versus single entity products of dolutegravir (DTG) and lamivudine (3TC) in healthy adult subjects.
- Trial name
- NCT03078556
- Testing
- Dolutegravir, Lamivudine, Dolutegravir + Lamivudine FDC Formulation 1
- Where
- United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Healthy
Visual Stimulus and Eye Movement
This study is designed to understand how we see visual patterns and how these patterns lead to eye movements. Normal volunteers participating in this study face a screen on which spots or patterns of light are projected.
- Trial name
- NCT00001172
- Where
- United States
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- National Eye Institute (NEI)
Influenza, Human
Pharmacokinetics of Zanamivir After Single and Repeated Dose Infusion Administration in Healthy Chinese Adults
Zanamivir is a potent and highly selective inhibitor of the influenza virus neuraminidase. Intravenous (IV) zanamivir is being developed for treatment of hospitalized patients with influenza, especially for those patients who may…
- Trial name
- NCT02377401
- Testing
- Zanamivir
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cardiovascular Diseases
Safety of Single Intravenous Administration of S95010 in Human Healthy Volunteers
The purpose of the study is to assess, the safety and tolerability of single ascending doses of S 95010 and to assess the pharmacokinetics (PK) of S 95010.
- Trial name
- NCT03494712
- Testing
- S 95010
- Where
- Belgium
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Institut de Recherches Internationales Servier
Healthy Volunteers
NasoShield Study of Safety and Immunogenicity
This study is a Phase 1, randomized, double-blind, placebo-controlled, dose-escalation clinical trial to evaluate the safety and immunogenicity of NasoShield in healthy adults 18 to 49 years of age.
- Trial name
- NasoShield (NCT03352466)
- Testing
- NasoShield, BioThrax
- Where
- 2 sites in United States
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Altimmune, Inc.
Type 2 Diabetes, Healthy Lifestyle Behaviors
Harnessing Human Potential and Improving Health Span in Women and Their Children
Women with Gestational Diabetes Mellitus (GDM) are 12-times more likely to develop Type 2 Diabetes (T2D) 4-6 years after delivery than women without GDM.
- Conditions
- Type 2 Diabetes, Healthy Lifestyle Behaviors, Gestational Diabetes
- Trial name
- HAPPY (NCT05949957)
- Testing
- LvL UP App, HAPPY App, Oura Ring And Oura App
- Where
- Singapore
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Institute for Human Development and Potential (IHDP), Singapore
Rotavirus Infections
Safety and Immunogenicity Study of the Recombinant Human Bovine Reassortant Rotavirus Vaccine in Healthy Indian Infants
A randomized, double-blind, placebo-controlled, staged dosage escalation study to evaluate the safety, tolerability, and immunogenicity of a 3-dose series of Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus…
- Trial name
- NCT00757926
- Testing
- Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine [BRV-TV]
- Where
- India
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Shantha Biotechnics Limited
Healthy, Elderly
Safety of Lactobacillus Rhamnosus GG Vs. Placebo in Elderly Subjects Receiving Trivalent Inactivated Influenza Vaccine
This is a phase I, randomized controlled trial to evaluate the safety of Lactobacillus rhamnosus GG (LGG) versus placebo in elderly subjects receiving the trivalent inactivated influenza vaccine.
- Trial name
- NCT01368029
- Testing
- Lactobacillus rhamnosus GG ATCC 53103 (LGG)
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Influenza Immunization, Healthy Volunteers
Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older
Primary Objective: To demonstrate that high-dose quadrivalent influenza vaccine (QIV-HD) induces an immune response that is superior to the responses induced by standard-dose quadrivalent influenza vaccine (QIV-SD) for all 4…
- Trial name
- NCT04024228
- Testing
- Standard-Dose influenza virus surface antigens (haemagglutinin and neuraminidase), Inactivated, Influenza Vaccine Quadrivalent, 2019-2020 Northern Hemisphere Strains (QIV-SD), High-Dose Influenza Vaccine (split virion, inactivated), Quadrivalent (QIV-HD) 2019-2020 Northern Hemisphere formulation
- Where
- 17 sites in Belgium, France and 4 more
- Volunteers
- 1,539 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg
The present study will evaluate the efficacy, immunogenicity and safety of one dose of OVX836 influenza vaccine 480μg, after intramuscular administration in healthy subjects aged 18-59 years.
- Trial name
- NCT05569239
- Testing
- OVX836 480µg, Saline Solution
- Where
- 16 sites in Belgium, Finland and 2 more
- Volunteers
- 2,891 people, healthy volunteers welcome
- Sponsor
- Osivax
Healthy
A First-in-Human Safety Trial of MTX-474
A randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and PK of single and multiple ascending doses of MTX-474 administered in…
- Trial name
- NCT06535841
- Testing
- MTX-474
- Where
- Australia
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Mediar Therapeutics
Influenza
Prospective Cohort Study to Evaluate Safety/Immunogenicity of Butantan Influenza Vaccine in Healthy Adults/Elderly
Prospective cohort study to evaluate safety and immunogenicity of the fragmented, inactivated trivalent Influenza vaccine produced at Butantan Institute in healthy adults and elderly.
- Trial name
- NCT02313740
- Testing
- Butantan Fragmented Inactivated Trivalent Influenza Vaccine
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.